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541Need for Permanent Pacemaker as a Complication of
Transcatheter Aortic Valve Implantation and Surgical Aortic Valve
Replacement in Elderly Patients With Severe Aortic Stenosis and
Similar Baseline Electrocardiographic Findings
Objectives The aim of this study was to compare the incidence and predictive factors of complete
atrioventricular block (AVB) and permanent pacemaker implantation (PPI) after transcatheter aortic
valve implantation (TAVI) versus surgical aortic valve replacement (SAVR).
Background No data exist on the need for PPI after TAVI versus SAVR in patients with similar base-
line electrocardiographic (ECG) ﬁndings.
Methods A total of 411 patients with severe aortic stenosis (AS) and no prior pacemaker who un-
derwent TAVI with the balloon-expandable Edwards valve (Edwards Lifesciences, Irvine, California)
were matched (1:1) with 411 elderly patients with severe AS who underwent isolated SAVR on the
basis of baseline ECG ﬁndings. The incidence, reasons, and predictive factors for PPI within 30 days
after the procedure were compared between groups.
Results Mean age was similar in both groups (p  0.11), and the TAVI group had a higher Society
of Thoracic Surgeons score (p  0.001). The rate of new PPI was higher after TAVI (7.3%) compared
with SAVR (3.4%), p  0.014. Complete AVB and severe symptomatic bradycardia, respectively, were
the reasons for PPI in the TAVI (5.6% and 1.7%, respectively) and SAVR (2.7% and 0.7%, respectively)
groups (p  0.039 for complete AVB, p  NS for symptomatic bradycardia). The presence of base-
line right bundle branch block was the only variable associated with PPI in the TAVI group (odds
ratio: 8.61, 95% conﬁdence interval: 3.14 to 23.67, p  0.0001), whereas no variable was found in
the SAVR group.
Conclusions Transcatheter aortic valve implantation was associated with a higher rate of complete
AVB and PPI compared with SAVR in elderly patients with severe AS and similar baseline ECG ﬁnd-
ings. The presence of baseline right bundle branch block correlated with the need for PPI in the
TAVI group. (J Am Coll Cardiol Intv 2012;5:540–51) © 2012 by the American College of Cardiology
FoundationThe occurrence of conduction abnormalities leading to the
need for permanent pacemaker implantation (PPI) remains
one of the most concerning complications associated with
transcatheter aortic valve implantation (TAVI), with an
incidence ranging from 9.3% to 42% among those patients
undergoing the procedure with a self-expandable valve
(CoreValve, Medtronic, Minneapolis, Minnesota) (1–11)
and from 2.5% to 11.5% after TAVI with a balloon-
expandable valve (Edwards valve, Edwards Lifesciences,
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high clinical relevance to determine the predictive factors of
conduction abnormalities and the need for PPI after a
TAVI procedure. Although some studies have already
identified several variables associated with the need for PPI
after TAVI with a self-expandable prosthesis (2–6,8,11),
very few data exist on the prediction of such a complication
after TAVI with a balloon-expandable valve. The occur-
rence of conduction disturbances and PPI is also a well-
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542known complication after surgical aortic valve replacement
(SAVR), with an incidence ranging from 3.2% to 8.5%
(17–23). However, most SAVR studies have included pa-
tients of very different ages and those undergoing coronary
artery bypass grafting during the same intervention as well
as those with both aortic stenosis (AS) and/or insufficiency
as the predominant underlying aortic valve disease. There-
fore, very few data exist on the post-operative need for PPI
in elderly patients undergoing isolated SAVR because of
pure/predominant severe AS, which has been the popula-
tion selected for TAVI up to now. Thus, the aims of this
study were: 1) to compare the incidence of PPI among
elderly patients with severe symp-
tomatic AS and similar baseline
electrocardiographic (ECG) abnor-
malities undergoing TAVI versus
isolated SAVR; and 2) to determine
factors associated with PPI after
TAVI and SAVR.
Methods
TAVI population. Between Janu-
ary 2005 and August 2010 a total of
551 patients underwent TAVI with
the balloon-expandable Edwards
valve (Cribier-Edwards, Edwards-
SAPIEN, or SAPIEN-XT, Ed-
wards Lifesciences, Irvine, Califor-
nia) for the treatment of severe
symptomatic AS in 3 Canadian
centers, St Paul’s Hospital, Vancou-
ver, British Columbia; the Quebec
Heart and Lung Institute, Quebec
City, Quebec; and Hamilton Gen-
eral Hospital, Hamilton, Ontario.
Of these, 140 patients were ex-
cluded for the following reasons:
prior pacemaker, cardiac resynch-
ronizations and/or implantable
cardioverter-defibrillators (n 
106), “valve-in-a-valve” procedures
or prior failed surgical bioprosthesis (n  17), and unsuccessful
rocedures leading to either procedural death or no valve
mplantation and precluding the analysis of post-procedural
onduction disturbances and PPI (n 17). Therefore, the final
AVI study population consisted of 411 patients (Fig. 1). All
linical, echocardiographic, procedural, and post-procedural
ata were prospectively gathered. The TAVI procedures have
een described in detail in previous reports (12). Temporary
ransvenous pacing was established, and valve implantation was
erformed under rapid ventricular pacing (160 to 220 beats/
Abbreviations
and Acronyms
1-AVB  first-degree
atrioventricular block
AS  aortic stenosis
AVB  atrioventricular block
CI  confidence interval
ECG  electrocardiogram/
electrocardiographic
IQR  interquartile range
IVCD  intraventricular
conduction disturbance
LAH  left anterior
hemiblock
LBBB  left bundle branch
block
OR  odds ratio
PPI  permanent pacemaker
implantation
RBBB  right bundle branch
block
SAVR  surgical aortic valve
replacement
SB  symptomatic
bradycardia
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantationin) in all cases. The temporary pacemaker was removed at the hnd of the TAVI procedure, and all patients were placed on
ontinuous ECG monitoring until hospital discharge.
The occurrence and timing of post-operative conduction
isturbances leading to PPI were prospectively recorded, as
ere the occurrence and timing of post-operative conduc-
ion disturbances managed by temporary pacing. The poli-
ies for PPI were in accordance with the American College
f Cardiology/American Heart Association/Heart Rhythm
ociety guidelines for device-based therapy of cardiac
hythm abnormalities (24), and PPI was indicated for
hird-degree and advanced second-degree atrioventricular
lock (AVB) at any anatomic level associated with post-
perative AVB that was not expected to resolve after the inter-
ention and for sinus node dysfunction with documented symp-
omatic bradycardia (SB), including frequent sinus pauses that
roduced symptoms.
SAVR population. A total of 900 consecutive elderly (70
years of age) patients underwent isolated SAVR for severe
symptomatic AS (as a predominant lesion) at the Quebec
Heart and Lung Institute between 2002 and 2010. The
clinical, echocardiographic, procedural, and post-procedural
data of all these patients had been prospectively gathered in
a database. A total of 120 patients were excluded for the
following reasons: prior SAVR (n  38); prior pacemaker,
cardiac resynchronizations, or implantable cardioverter-
defibrillators (n  65); and concomitant aortic root replace-
ment procedures (n 17), leading to a cohort of 780 SAVR
atients (Fig. 1).
Surgical AVR procedures were performed through a
idline sternotomy, with standard techniques. Temporary
picardial leads were inserted at the end of the intervention
n all patients and maintained until hospital discharge. The
atients were placed on continuous ECG monitoring until
Figure 1. Flow Chart of the Study Population
ECG  electrocardiographic; SAVR  surgical aortic valve replacement.ospital discharge. The occurrence and timing of post-
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543operative conduction disturbances leading to PPI were
prospectively recorded, as were the occurrence and timing of
post-operative conduction disturbances managed by tempo-
rary pacing. The policies for PPI followed the same criteria
as for the TAVI population (24).
Matching process for baseline ECG ﬁndings. For the purpose
f this study the baseline ECGs obtained within the 24 h
efore TAVI and SAVR were analyzed by 2 investigators
naware of the clinical data for the presence of conduction
bnormalities as defined by the American Heart Associa-
ion/American College of Cardiology Foundation/Heart
hythm Society recommendations for the standardization
nd interpretation of the ECG (25). Patients were classified
ith respect to the presence of baseline conduction distur-
ances as follows: no conduction disturbances, left bundle
ranch block (LBBB), first-degree atrioventricular block
1-AVB), right bundle branch block (RBBB), left anterior
emiblock (LAH), intraventricular conduction disturbance
IVCD) (defined as the presence of QRS duration110 ms
ithout a pattern with RBBB or LBBB criteria) (25),
BBB  1-AVB, RBBB  1-AVB, RBBB  LAH,
BBB  LAH  1-AVB, LAH  1-AVB, and IVCD 
1-AVB (Table 1). Within each ECG-subgroup, each TAVI
patient was matched (1:1 ratio) with an SAVR patient with
identical ECG findings. Considering that there was more
than 1 SAVR patient who could potentially be matched
with each TAVI patient in 9 of the 12 ECG-subgroups
(Table 1), the final matching was performed by random
sampling without replacement with the bootstrap method.
This led to a final study population of 411 patients/group
with identical ECG findings (Fig. 1).
Table 1. Preprocedural ECG Findings of 411 TAVI Versus
SAVR-Matched Patients
Conduction
Disturbances
411 TAVI
Patients
780 SAVR Patients
(Before Matching)
411 SAVR Patients
(After Matching)
No conduction
disturbances
209 (50.8) 491 (62.9) 209 (50.8)
LBBB 33 (8.0) 43 (5.5) 33 (8.0)
LBBB  1-AVB 5 (1.2) 9 (1.2) 5 (1.2)
RBBB 20 (4.9) 34 (4.4) 20 (4.9)
RBBB  1-AVB 2 (0.5) 2 (0.3) 2 (0.5)
RBBB  LAH 14 (3.4) 17 (2.2) 14 (3.4)
RBBB  1-AVB  LAH 1 (0.2) 4 (0.5) 1 (0.2)
LAH 29 (7.1) 47 (6.0) 29 (7.1)
LAH  1-AVB 3 (0.7) 3 (0.4) 3 (0.7)
IVCD 43 (10.5) 46 (5.9) 43 (10.5)
IVCD  1-AVB 14 (3.4) 14 (1.8) 14 (3.4)
1-AVB 38 (9.3) 70 (8.9) 38 (9.3)
Values are n (%).
1-AVB first-degree atrioventricular block; ECG electrocardiographic; IVCD intraventric-
ular conduction disturbance; LAH  left anterior hemiblock; LBBB  left bundle branch block;
RBBB right bundle branch block; SAVR surgical aortic valve replacement; TAVI transcath-Seter aortic valve implantation.Statistical analysis. Qualitative variables were expressed as
percentages, and quantitative variables were expressed as
mean  SD or median (25th to 75th interquartile range
[IQR]), depending on variable distribution. The normality
of distribution of continuous variables was verified with the
Shapiro–Wilk test, and logarithmic transformation was
performed if necessary. Continuous variables were com-
pared with the Student t test or Wilcoxon rank-sum test for
independent samples and the paired Student t test for
matched groups and comparisons within groups. Categori-
cal data were compared with the chi-square or Fischer exact
tests for independent samples and the conditional logistic
regression analysis for matched groups. A stepwise logistic
regression analysis, including all variables with a p value
0.2 in the univariate analysis, was used to determine the
independent predictors of PPI in both TAVI and SAVR
groups. The variables included into the multivariate model
were no conductions disturbances, RBBB and RBBB 
1-AVB  LAH for the TAVI group, and prior coronary
artery bypass grafting and RBBB  1-AVB for the SAVR
group. A propensity score analysis was performed to adjust
for the intergroup (TAVI vs. SAVR) differences in baseline
characteristics caused by the selection bias inherent to the
nonrandomized nature of the study. A propensity score
representing the likelihood of having TAVI as opposed to
SAVR was calculated for each patient with a logistic
regression analysis that identified variables independently
associated with the type of procedure. Variables exhibiting a
p value 0.2 in the univariate analysis were included in the
logistic regression analysis. Body mass index, hypertension,
previous myocardial infarction, previous open heart surgery,
previous percutaneous coronary intervention, cerebrovascu-
lar disease, chronic obstructive pulmonary disease, chronic
kidney disease, aortic valve area, and pulmonary hyperten-
sion were independently associated with the type of proce-
dure and were used to calculate the propensity score. The
calculated propensity score was then incorporated into the
multivariable regression model, and PPI rate at 30 days was
analyzed with a logistic regression analysis adjusted for
propensity score.
Differences were considered statistically significant at p
values 0.05. The data were analyzed with SAS statistical
software (version 9.2, SAS Institute, Inc., Cary, North
Carolina).
Results
Baseline clinical and echocardiographic characteristics of
the study population and the main procedural data accord-
ing to the type of procedure (TAVI vs. SAVR) are shown in
Table 2. The echocardiography performed at hospital dis-
charge showed a significant reduction in mean aortic gra-
dient (TAVI: from 44  16 mm Hg to 11  4 mm Hg;AVR: from 48  16 mm Hg to 14  5 mm Hg, p 
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5440.0001 for both) and an increase in aortic valve area (TAVI:
from 0.62  0.16 cm2 to 1.53  0.34 cm2; SAVR: from
.65  0.18 cm2 to 1.38  0.39 cm2, p  0.0001 for both).
Need for PPI after TAVI and SAVR procedures. The need for
PI after TAVI and SAVR procedures is shown in Figure 2.
total of 44 patients (5.3%) had PPI at 30-day follow-up,
0 patients in the TAVI group (7.3%), and 14 patients in
he SAVR group (3.4%) (odds ratio [OR]: 2.23, 95%
onfidence interval [CI]: 1.17 to 4.27, p 0.014; OR: 2.69,
95% CI: 1.08 to 6.69, p  0.030) (after the adjustment for
propensity score analysis with a C-statistic of 0.61 [95% CI:
0.52 to 0.69, p  0.013]). The reasons for PPI were
complete AVB (TAVI: n  23, 77%, SAVR: n  11, 79%
[5.6% and 2.7% among the whole population, respectively],
p  0.039) and severe SB (TAVI: n  7, 23%, SAVR: n 
3, 21% [1.7% and 0.7% among the whole population,
respectively], p  0.22). In the TAVI group, most (n  23,
Table 2. Clinical Characteristics and Procedural Variables According to
the Type of Treatment: TAVI Versus SAVR
Variables
TAVI SAVR
p Value(n  411) (n  411)
Clinical characteristics
Age (yrs) 81 11 80 4 0.21
Male 176 (43) 181 (44) 0.90
Body mass index (kg/m2) 26 5 27 5 0.0001
Diabetes 119 (29) 83 (20) 0.005
Hypertension 326 (79) 275 (67) 0.0001
NYHA functional class
I–II 46 (11) 184 (45) 0.0001
III–IV 365 (89) 227 (55)
Chronic atrial ﬁbrillation/ﬂutter 96 (23) 81 (20) 0.11
Previous myocardial infarction 186 (45) 57 (14) 0.0001
Previous percutaneous coronary
intervention
171 (42) 28 (7) 0.0001
Prior coronary artery bypass grafting 135 (33) 30 (7) 0.0001
Cerebrovascular disease 99 (24) 41 (10) 0.0001
Peripheral vascular disease 123 (30) 49 (12) 0.0001
Chronic obstructive pulmonary
disease
115 (28) 69 (17) 0.0001
Porcelain aorta 73 (18) 0 —
Estimated glomerular ﬁltration rate
60 ml/min/1.73 m2
246 (60) 147 (36) 0.0001
STS score (%) 9.2 5.7 3.6 1.5 0.0001
Logistic EuroSCORE (%) 26 17 12 9 0.0001
Echocardiographic data
Left ventricular ejection fraction (%) 54 14 59 13 0.0001
Mean gradient (mm Hg) 44 16 47 16 0.022
Aortic valve area (cm2) 0.62 0.16 0.65 0.18 0.018
Pulmonary artery systolic pressure
(mm Hg)
45 15 39 14 0.0001
Moderate/severe mitral regurgitation 101 (25) 22 (5) 0.0001
Continued in next column73%) conduction disturbances leading to PPI occurred
during the procedure (complete AVB, median 0 h, IQR: 0
to 24 h) and were managed either conservatively or with
temporary pacing for a median of 2 days (IQR: 0 to 2 days)
until PPI. The timing of procedural complete AVB (avail-
able in 17 patients) was as follows: 1) after crossing the native
aortic valve with the straight wire (n 2); 2) immediately after
balloon valvuloplasty (n  9); and 3) immediately after valve
prosthesis deployment (n  6). In the remaining 8 patients
(27%) conduction disturbances leading to PPI occurred at a
median time of 60 h (IQR: 24 to 96 h) and were managed
either conservatively or with temporary pacing until PPI.
Among the SAVR group, conduction disturbances leading
to PPI occurred at a median of 12 h (IQR: 0 to 24 h) after
the procedure (p  0.36 compared with TAVI) and were
managed either conservatively or with temporary pacing
during a median of 6 days (IQR: 4 to 9 days) until PPI
(p  0.001 compared with TAVI). The PPI was performed
Table 2. Continued
Variables
TAVI SAVR
p Value(n  411) (n  411)
Procedural variables
Transcatheter approach
Transfemoral 223 (54) — —
Transapical 188 (46) — —
Transcatheter prosthesis
Prosthesis size (mm)
23 187 (45) — —
26 223 (54) — —
29 1 (1) — —
Prosthesis type
Cribier-Edwards 48 (12) — —
Edwards-SAPIEN 344 (84) — —
SAPIEN-XT 19 (5) — —
Surgical prosthesis
Prosthesis size (mm)
19 — 42 (10) —
21 — 126 (31) —
23 — 118 (29) —
25 — 88 (21) —
27 — 33 (8) —
29 — 4 (1) —
Prosthesis type
Mechanical valve — 14 (3) —
Bioprosthesis — 397 (97) —
Stented — 365 (89) —
Stentless — 32 (8) —
Hospital stay length 7 (5–10) 8 (6–11) 0.0001
Values are mean  (SD), n (%), or median (25th to 75th interquartile range), unless otherwise
noted.
EuroSCORE European system for cardiac operative risk evaluation; NYHA New York Heart
Association functional class; SAVR surgical aortic valve replacement; STS Society of ThoracicSurgeons; TAVI transcatheter aortic valve implantation.
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545at a median of 2 days (IQR: 0 to 4 days) after TAVI,
compared with 6 days (IQR: 4 to 9 days) after SAVR (p 
0.001). Details about the timing of complete AVB/severe
SB occurrence and the timing of PPI after TAVI and SAVR
procedures are shown in Figures 3 and 4, respectively. Data
bout the rhythm at hospital discharge were available in 31 of
he 44 patients who had PPI during index hospital stay (20 in
he TAVI group, and 11 in the SAVR group). In the TAVI
roup, 80% of the patients who required PPI were under
ace-rhythm at hospital discharge (94% if PPI was due to
omplete AVB, and 25% if PPI was due to severe bradycardia)
Fig. 5). In the SAVR group, 73% of the patients who required
PI were under pace-rhythm at hospital discharge (70% if PPI
as due to complete AVB, and 100% if PPI was due to severe
radycardia) (Fig. 5).
In the SAVR group, 17 patients (4.1%) complicated with
ransient high-degree/complete AVB (n  6) or severe SB
n 11) that were managed with temporary pacing, with no
eed for later PPI. The median time from SAVR to these
ransient conduction abnormalities was 24 h (IQR: 24 to
8 h), and the median duration for temporary pacing was
6 h (IQR: 3 to 60 h). In the TAVI group, 2 patients (0.5%)
resented with transient complete AVB during the proce-
ure that was managed only with temporary pacing for a few
inutes, with no PPI (p  0.001 vs. SAVR).
Factors associated with PPI after TAVI and SAVR. Clinical,
echocardiographic, baseline ECG findings and procedural
variables of the TAVI population grouped according to the
need for PPI after the procedures are shown in Table 3. In
the multivariate analysis, RBBB was the only independent
variable associated with PPI after TAVI (OR: 8.61, 95%
CI: 3.14 to 23.67, p  0.0001). Clinical, echocardio-
graphic, baseline ECG findings and procedural variables
Figure 2. Permanent Pacemaker Implantation After TAVI and SAVR
Percentage of patients who needed a permanent pacemaker within 30 days
after transcatheter aortic valve implantation (TAVI) or surgical aortic valve
replacement (SAVR) procedures for the treatment of severe aortic stenosis.of the SAVR population grouped according to the needfor PPI are shown in Table 4. No variable was found to
be associated with PPI after SAVR in the multivariate
analysis.
Discussion
This multicenter case-match study—including a large co-
hort of elderly patients diagnosed with severe symptomatic
AS, no prior pacemaker, and similar baseline ECG find-
ings—showed that TAVI was associated with a higher rate
of PPI (7.3%) compared with SAVR (3.4%). The main
reason for PPI was complete AVB (TAVI: 5.6%, SAVR:
2.7%), followed by severe SB (TAVI: 1.7%, SAVR: 0.7%).
In both groups, most conduction disturbances leading to PPI
occurred either during or within the 24 h after the procedure,
but PPI was performed earlier in the TAVI group (2 days)
compared with the SAVR group (6 days). Of note, no episodes
of complete AVB occurred after 48 h after TAVI. Also, the use
of temporary pacing for the management of transient complete
AVB or severe SB was more frequent in the SAVR group
(4.1%) compared with the TAVI group (0.5%). The presence
of RBBB at baseline ECG was associated with PPI in the
TAVI group, whereas no variable was found to be associated
with PPI in the SAVR group.
PPI after TAVI. Previous studies on TAVI using the balloon-
expandable Edwards valve have reported a rate of PPI
within the 30 days after the procedure of between 2.5% and
11.5%, although most studies did not exclude those patients
with pre-procedural pacemaker from the PPI analysis
(6,7,12–16). Also in accordance with previous studies, the
present study has shown that the occurrence of complete
AVB was the reason for PPI in most cases. Interestingly, it
has been shown that TAVI with a balloon-expandable valve
is associated with the occurrence of new conduction distur-
bances, specifically new complete LBBB, in 12% to 21% of
patients (6,14,26). Any direct trauma or mechanical stress to
the His-bundle at the region of the membranous septum
and right trigone beneath the noncoronary/right coronary
cusps (Fig. 6) might explain the occurrence of new conduc-
tion abnormalities leading to complete AVB after TAVI.
The present study has shown that the vast majority (87%) of
complete AVBs occurred at the time of the TAVI proce-
dure, further supporting the mechanism of direct trauma to
the conduction system during balloon dilation/valve expan-
sion as the main cause for the conduction disturbances
leading to PPI. Importantly, the rate of conduction distur-
bances and PPI after TAVI might vary according to the type
of transcatheter valve. While TAVI with a balloon-
expandable valve (Edwards valve) has been nearly system-
atically associated with an incidence of PPI lower than 10%
(6,7,12–16), the use of the self-expandable CoreValve
prosthesis has been associated with a rate of PPI of
approximately 25%, ranging from 9.3% to up to 42% (1–11).
These differences might be explained by differences in the
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546design of the 2 devices, with the CoreValve being a much
longer device with a longer segment of the stent containing
Figure 3. Time to Conduction Abnormalities After TAVI and SAVR
Timing of the occurrence of conduction abnormalities (complete atrioventricul
after transcatheter aortic valve implantation (TAVI) and surgical aortic valve re
complete atrioventricular block. (C) Time to severe bradycardia.the valve entering into the left ventricular outflow tract andpotentially increasing the interference with the conduction
system. Also, the stent containing the CoreValve prosthesis
ck or severe bradycardia) leading to permanent pacemaker implantation
ent (SAVR) procedures. (A) Time to any conduction abnormality. (B) Time toar blo
placemis made of nitinol, which might result in continued outward
alve im
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547pressure and expansion after valve deployment. This might
partially explain why a significant number of conduction
disturbances leading to PPI after CoreValve implantation
occur not only at the time of the procedure but during the
following days (4,5,27,28). This might translate into dif-
ferences with regard to the management and monitoring
of patients after the procedure, depending on the type of
transcatheter valve. Smith et al. (29) reported similar
rates of PPI in patients undergoing TAVI with a balloon-
expandable valve (3.8%) versus SAVR (3.6%) in the
Figure 4. Time to Permanent Pacemaker Implantation After TAVI and SAVR
Time to permanent pacemaker implantation (days) after transcatheter aortic v
Figure 5. Pace Rhythm at Hospital Discharge
Pace rhythm at hospital discharge among the patients who had permanent
pacemaker implantation during index hospital stay. SAVR  surgical aortic
valve replacement; TAVI  transcatheter aortic valve implantation.PARTNER (Placement of Aortic Transcatheter Valve)
trial. However, up to 21% of the patients had prior pace-
maker and no data on baseline ECG and conduction
disturbances before the TAVI procedure were provided.
Also, the PPI rate observed in the PARTNER trial was
among the lowest ever reported after TAVI with a balloon-
expandable valve (6,7,12–16). Unlike TAVI registries that
included consecutive series of patients, the PARTNER trial
included a selected group of patients, and one might wonder
whether this could have influenced the PPI results.
Very few studies including a small number of patients
have evaluated the pre-procedural predictors of PPI after
TAVI with a balloon-expandable valve (6,14). The present
study showed, for the first time, that the presence of
pre-existing RBBB independently correlated with a higher
risk of complete AVB and PPI after TAVI with a balloon-
expandable valve. Thirty-five percent of the patients with
prior RBBB had complete AVB and needed PPI after the
procedure, compared with only 5.9% of the patients with no
prior RBBB. This is in accordance with the study that
reported the occurrence of new LBBB in up to 21% of the
patients after TAVI with a balloon-expandable valve (26).
Prior studies with the CoreValve prosthesis also identified
the presence of RBBB as one of the main predictors of PPI
after TAVI (5,6,8,11).
PPI after SAVR. The occurrence of conduction disturbances
and the need for PPI is a well-known complication after
cardiac surgery (17–22), but most studies including SAVR
plantation (TAVI) and surgical aortic valve replacement (SAVR) procedures.patients have also included coronary artery bypass grafting
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548as a concomitant intervention. Keefe et al. (18) and Dawk-
ins et al. (22) reported a PPI rate of 3.3% and 8.5%,
respectively, after isolated SAVR. However, both studies
included patients with a wide age range as well as aortic
stenosis and regurgitation as the main underlying aortic
diseases. It is well known that aortic regurgitation is one of
the most important predictive factors of PPI after SAVR
(21). We have previously reported a PPI rate of 3.2% after
isolated SAVR in elderly patients with severe AS (23). In
accordance with these results, the incidence of PPI in the
surgical cohort of the PARTNER trial was 3.6% (29). The
present study, which evaluated the occurrence of conduction
disturbances and the need for PPI in elderly patients
undergoing isolated SAVR due to AS, showed a PPI rate of
3.4% after the intervention. Most patients underwent PPI
due to complete AVB, and a minority underwent PPI
because of severe SB. Although several previous studies had
identified the presence of baseline conduction disturbances
Table 3. Clinical Characteristics, Procedural Variables, and
Pre-Procedural ECG Findings, According to the Need for PPI After TAVI
Variables
PPI
p Value
Yes
(n  30)
No
(n  381)
Clinical characteristics
Age (yrs) 80 16 81 10 0.68
Male 14 (47) 162 (43) 0.70
Body mass index (kg/m2) 26 5 26 5 0.93
Diabetes 8 (27) 111 (29) 0.84
Hypertension 27 (90) 299 (78) 0.16
NYHA functional class
I–II 3 (10) 43 (11) 0.97
III–IV 27 (90) 338 (89)
Chronic atrial ﬁbrillation/ﬂutter 4 (13) 92 (24) 0.26
Previous myocardial infarction 10 (33) 174 (46) 0.25
Prior coronary artery bypass grafting 8 (27) 127 (33) 0.55
Cerebrovascular disease 7 (23) 93 (24) 1.00
Peripheral vascular disease 6 (20) 117 (31) 0.39
Chronic obstructive pulmonary
disease
7 (23) 108 (28) 0.68
Porcelain aorta 4 (13) 69 (18) 0.63
Estimated glomerular ﬁltration rate
60 ml/min/1.73 m2
21 (70) 225 (59) 0.33
STS score (%) 9.1 4.3 9.2 5.8 0.90
Logistic EuroSCORE (%) 27 19 26 17 0.79
Echocardiographic data
Left ventricular ejection fraction (%) 57 11 54 15 0.33
Mean gradient (mm Hg) 41 16 45 16 0.22
Aortic valve area (cm2) 0.65 0.15 0.62 0.16 0.35
Pulmonary artery systolic pressure
(mm Hg)
46 16 45 15 0.84
Moderate/severe mitral regurgitation 9 (30) 95 (24) 0.51
Continued in next columnas a predictor of PPI after SAVR (17,20,22,23), we failed to
identify any independent predictive factor of PPI in our
study. This probably highlights the importance of technical
procedural aspects as well as the severity of valve calcifica-
tion in the occurrence of some injury of the conduction
system during the procedure leading to conduction abnor-
malities and PPI. Importantly, unlike TAVI procedures,
only one-half of the AV conduction abnormalities occurred
during the procedure, whereas the other one-half occurred
within the first few hours/days after the procedure.
Study limitations. Although baseline and procedural data
ad been prospectively collected, one of the main limitations
f the study lies in the nonrandomized nature of the
omparison between TAVI and SAVR, which led to sig-
ificant differences in between-group baseline characteris-
ics. Also, the low number of events (n 14) contributed to
he inability to identify factors associated with PPI after
AVR. Although SAVR patients had systematic temporary
picardial leads in place up to hospital discharge, temporary
Table 3. Continued
Variables
PPI
p Value
Yes
(n  30)
No
(n  381)
Baseline conduction disturbances
No conduction disturbances 9 (30) 200 (52) 0.02
LBBB 1 (3) 32 (8) 0.50
LBBB  1-AVB 0 5 (1) 1.00
RBBB 7 (23) 13 (3) 0.0001
RBBB  1-AVB 1 (3) 1 (0.3) 0.14
RBBB  LAH 2 (7) 12 (3) 0.27
RBBB  1-AVB  LAH 1 (3) 0 0.07
LAH 3 (10) 26 (7) 0.46
LAH  1-AVB 0 3 (0.8) 1.00
IVCD 3 (10) 40 (11) 1.00
IVCD  1-AVB 2 (7) 12 (3) 0.27
1-AVB 1 (3) 37 (10) 0.34
Procedural variables
Transcatheter approach
Transfemoral 15 (50) 208 (55) 0.70
Transapical 15 (50) 173 (45)
Prosthesis type
Cribier-Edwards 4 (13) 44 (12) 0.72
Edwards-SAPIEN 24 (80) 320 (84)
SAPIEN-XT 2 (7) 17 (5)
Prosthesis size (mm)
23 16 (53) 171 (45) 0.49
26 14 (47) 209 (55)
29 0 1 (0.3)
Ratio aortic annulus/prosthesis size 0.88 0.9 0.88 0.8 0.80
Hospital stay length 8 (6–15) 6 (4–10) 0.018
Values are n (%), mean (SD), or median (25th to 75th interquartile range).PPI permanent pacemaker implantation; other abbreviations as in Tables 1 and 2.
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549pacemaker leads were routinely removed after the TAVI
procedure in the absence of procedural conduction abnor-
malities. A potential influence of these differences in tem-
porary pacing on the final rate of PPI between groups
cannot be excluded. However, most conduction distur-
bances in the TAVI group occurred during the procedure
and most patients were initially managed either conserva-
tively or with temporary pacing for a median of 2 days
before PPI. Also, the vast majority (90%) of the patients
who had PPI due to complete AVB were in paced rhythm
at hospital discharge. Therefore, it is unlikely that differ-
ences in temporary pacing management would have had a
significant influence on the differences in PPI between
groups. Finally, no assessment was made on valve calcification
pattern/distribution and the ventricular depth of the valve
prosthesis, which have been identified as predictors of conduc-
Table 4. Clinical Characteristics, Procedural Variables, and
Preprocedural ECG Findings, According to the Need for PPI After SAVR
Variables
PPI
p Value
Yes
(n  14)
No
(n  397)
Clinical characteristics
Age (yrs) 81 5 80 4 0.33
Male 8 (57) 173 (44) 0.41
Body mass index (kg/m2) 27 5 27 4 0.51
Diabetes 2 (14) 81 (20) 0.74
Hypertension 9 (64) 266 (67) 0.78
NYHA functional class
I–II 6 (43) 178 (45) 0.96
III–IV 8 (57) 219 (55)
Chronic atrial ﬁbrillation/ﬂutter 4 (29) 77 (19) 0.49
Previous myocardial infarction 3 (21) 54 (14) 0.42
Previous percutaneous coronary
intervention
1 (7) 27 (7) 1.00
Prior coronary artery bypass grafting 3 (21) 27 (7) 0.07
Cerebrovascular disease 1 (7) 40 (10) 1.00
Peripheral vascular disease 0 49 (12) 0.39
Chronic obstructive pulmonary
disease
4 (29) 65 (16) 0.27
Estimated glomerular ﬁltration rate
60 ml/min/1.73 m2
2 (14) 145 (37) 0.15
STS score (%) 3.5 1.6 3.6 1.5 0.87
Logistic EuroSCORE (%) 18 14 12 8 0.17
Echocardiographic data
Left ventricular ejection fraction (%) 57 20 59 13 0.65
Mean gradient (mm Hg) 46 16 47 16 0.83
Aortic valve area (cm2) 0.70 0.2 0.64 0.2 0.81
Pulmonary artery systolic pressure
(mm Hg)
43 20 39 14 0.51
Moderate/severe mitral regurgitation 0 22 (6) 1.00
Continued in next columntion abnormalities and PPI after TAVI (2,3,8). The absence of
standardized echocardiographic and/or angiographic images at
the end of the TAVI procedure among the participating
centers precluded a reliable measurement of the ventricular
depth of the valve prosthesis in the present study.
Conclusions
Transcatheter aortic valve implantation with a balloon-
expandable valve was complicated with the need for PPI
after the procedure in 7.3% of the patients, a rate signifi-
cantly higher than the rate of 3.4% observed in SAVR
patients with similar baseline ECG abnormalities. Most
patients in both groups needed PPI because of complete
AVB occurring either during or within 24 h after the
procedure in most cases. Finally, the presence of pre-
existing RBBB was a powerful risk factor for PPI in the
TAVI group but not in the SAVR group. Transcatheter
Table 4. Continued
Variables
PPI
p Value
Yes
(n  14)
No
(n  397)
Baseline conduction disturbances
No conduction disturbances 5 (36) 204 (51) 0.29
LBBB 1 (7) 32 (8) 1.00
LBBB  1-AVB 1 (7) 4 (1) 0.16
RBBB 1 (7) 19 (5) 0.51
RBBB  1-AVB 1 (7) 1 (0.3) 0.07
RBBB  LAH 0 14 (4) 1.00
RBBB  1-AVB  LAH 0 1 (0.3) 1.00
LAH 1 (7) 28 (7) 1.00
LAH  1-AVB 0 3 (0.8) 1.00
IVCD 3 (21) 40 (10) 0.17
IVCD  1-AVB 0 14 (4) 1.00
1-AVB 1 (7) 37 (9) 1.00
Procedural variables
Prosthesis size (mm)
19 0 42 (11) 0.73
21 5 (36) 121 (30)
23 4 (29) 114 (29)
25 3 (21) 85 (21)
27 2 (14) 31 (8)
29 0 4 (1)
Prosthesis type
Mechanical valve 0 14 (4) 1.00
Bioprosthesis 14 (100) 383 (96)
Stented 13 (93) 352 (89) 1.00
Stentless 1 (7) 31 (8)
Cardiopulmonary bypass time (min) 94.6 35.8 87.1 26.6 0.32
Aortic cross-clamp time (min) 67.5 21.8 64.3 19.8 0.57
Hospital stay length 10 (9–12) 8 (6–11) 0.073
Values are n (%), mean (SD), or median (25th to 75th interquartile range).Abbreviations as in Tables 1, 2, and 3.
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550aortic valve implantation has become a well-established
treatment for very high- or prohibitive-surgical-risk pa-
tients with AS and might become an option for a
lower-risk population in the near future. These results
should help to better identify the patients at risk for PPI
after the procedure and contribute to an improved clinical
decision making process in patients eligible for either
TAVI or SAVR.
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